Department of Gastroenterology Dr. Meral Sözen Clinic, Ufuk Üniversitesi Straat, The Paragon Tower Çukurambar No:17-3 Çankaya, Türkiye-06530

In this study, individuals with Recurrent hepatitis B with HBeAg-negative  have their liver fibrosis and inflammation assessed using non-invasive diagnostic assays for accuracy and clinical value. In order to ascertain how well these techniques differentiate between HBeAg-negative CHB and dormant carriers of the hepatitis B surface antigen it contrasts them with conventional liver biopsies. The study also investigates how these tests might be used to track the effectiveness of antiviral therapy. Blood-based indices were evaluated, including the APRI ratio, the fibrosis-iv index, the neutrophil-to-lymphocyte (N/L) ratio, and the alanine aminotransferase-to-aspartate aminotransferase (AAR) ratio. Results highlight the potential of non-invasive methods as reliable alternatives to liver biopsy, paving the way for improved management of CHB. Two participant groups were established according to the METAVIR grading scheme. Each participant underwent measurements of several clinical indices, including the fibrosis-4 index, the (N/L) ratio, the alanine aminotransferase to AAR ratio, and APRI ratio." The mean platelet volume (MPV), AAR, FIB-4, APRI, N/L ratio, and platelet count had AUROC values of 0.581, 0.558, 0.502, 0.505, 0.506, and 0.460, respectively. To determine if fibrosis was substantial or progressed, platelet counts were employed (METAVIR ≥2). APRI, FIB-4, N/L ratio, MPV, AAR, for detecting severe fibrosis (METAVIR = 2), and platelet count exhibited corresponding AUROCs of 0.473, 0.451, 0.484, 0.503, 0.525, and 0.605. Clinical evaluations for each participant included determining several indices: the fibrosis-4 (FIB-4) index, the ratio of (N/L), the ratio of APRI to AAR, and the ratio of aspartate aminotransferase to platelets (APRI)." According to our research, severe fibrosis has only been partially detected via non-invasive diagnostic methods like APRI and FIB-4. Due to its unreliability, liver biopsies cannot currently be used in place of these assays. They are only applicable to individuals who do not make excellent liver biopsies